Latest News about BMY
Recent news which mentions BMY
   Bristol Myers Squibb's Combo Therapy Shows Sustained Benefits Over Pfizer's Cancer Drug In Kidney Cancer Patients After 8 Years Of Followup
   
  
  
  January 23, 2024
  From Benzinga
 From Benzinga
 
   Bristol Myers' Lead Cancer Immunotherapy Shows Progression Free Survival Versus Chemo In Certain Type Of Colorectal Cancer
   
  
  
  January 22, 2024
  From Benzinga
 
   Ikena Oncology Refocuses on Key Programs: Analysts Maintain Outperform Ratings Amid Strategic Organizational Changes
   
  
  
  January 19, 2024
  From Benzinga
 
   Inflation-Busting Price Hikes For Ozempic, Mounjaro And Others: Are Drugmakers Profiteering?
   
  
  
  January 18, 2024
  From Benzinga
 
   Behind the Scenes of Bristol-Myers Squibb's Latest Options Trends
   
  January 16, 2024
  Tickers 
   BMY
  
  
  From Benzinga
 
   Financial Relief For Medicare Patients: Part D Overhaul Caps Out-of-Pocket Drug Cost Limits
   
  
  
  January 16, 2024
  From Benzinga
 
   Cytokinetics' Heart Drug Is A Multi-Billion Dollar Opportunity By 2032 Despite Novartis Setback: Analyst
   
  
  
  January 12, 2024
  From Benzinga
 
   5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday
   
  
  
  January 08, 2024
  From Benzinga
 
   3 Magnificent High-Yield Dividend Stocks to Buy in 2024
   
  
  
  January 06, 2024
  From Motley Fool
 
   Strides Toward Lower Drug Costs: Florida Becomes First To Receive Nod To Import Prescription Drugs from Canada
   
  
  
  January 05, 2024
  From Benzinga
 
   Looking Into Bristol-Myers Squibb's Recent Short Interest
   
  January 05, 2024
  Tickers 
   BMY
  
  
  From Benzinga
 
   3 Dividend Stocks for Strong Returns in 2024 and Beyond
   
  
  
  January 04, 2024
  From InvestorPlace
 
   10 Health Care Stocks Whale Activity In Today's Session
   
  
  
  January 04, 2024
  From Benzinga
 
   7 Stocks Primed for a Spectacular Comeback in 2024
   
  
  
  January 03, 2024
  From InvestorPlace
 
   This Analyst Downgrades Bristol-Myers Squibb, Cautions Amid Product Launch And Revenue Concerns
   
  
  
  January 03, 2024
  From Benzinga
 
   3 Strong Dividend Stocks to Buy Early On in 2024
   
  
  
  January 03, 2024
  From Motley Fool
 
   Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
   
  
  
  December 29, 2023
  From Benzinga
 
   Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
   
  
  
  December 29, 2023
  From Benzinga
 
   Cytokinetics' Drug Potential: Analyst Suggests Key Role Of Established Pharma For Potential Launch
   
  
  
  December 28, 2023
  From Benzinga
 
   Pharmaceutical Giants Brace for Showdown as Medicare Drug Price Negotiations Are Poised For 2024
   
  
  
  December 28, 2023
  From Benzinga
 
   Why Is Blood Purification Focused CytoSorbents Trading Lower Today?
   
  
  
  December 28, 2023
  From Benzinga
 
   Why Is Cytokinetics (CYTK) Stock Up 70% Today?
   
  
  
  December 27, 2023
  From InvestorPlace
 
   Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned
   
  
  
  December 27, 2023
  From Benzinga
 
   Meta To Rally Over 18%? Here Are 10 Top Analyst Forecasts For Wednesday
   
  
  
  December 27, 2023
  From Benzinga
 
   Bristol-Myers' Acquisition Of Karuna Therapeutics Paves Way For Aggressive Global Marketing Of KarXT: Analyst
   
  
  
  December 26, 2023
  From Benzinga
 
   Why Is RayzeBio (RYZB) Stock Up 100% Today?
   
  
  
  December 26, 2023
  From InvestorPlace
 
   Health Care Company Bristol-Myers Squibb Announces Merger With RayzeBio
   
  
  
  December 26, 2023
  From Benzinga
 
   Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  
  
 Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  © 2025 FinancialContent. All rights reserved.